EP Patent

EP1515743A2 — Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis

Assigned to Merck Serono SA · Expires 2005-03-23 · 21y expired

What this patent protects

The invention relates to the use of osteoprotegerin for treatment and/or prevention of fibrotic diseases, in particular of scleroderma.

USPTO Abstract

The invention relates to the use of osteoprotegerin for treatment and/or prevention of fibrotic diseases, in particular of scleroderma.

Drugs covered by this patent

Patent Metadata

Patent number: EP1515743A2
Jurisdiction: EP
Classification: —
Expires: 2005-03-23
Drug substance claim: No
Drug product claim: No
Assignee: Merck Serono SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.